IRIS
IACOBELLI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.375
EU - Europa 4.952
AS - Asia 3.105
SA - Sud America 267
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 4
Totale 13.731
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.358
SG - Singapore 1.217
CN - Cina 989
UA - Ucraina 967
IE - Irlanda 847
GB - Regno Unito 665
SE - Svezia 609
TR - Turchia 587
FR - Francia 572
IT - Italia 486
DE - Germania 314
BR - Brasile 245
FI - Finlandia 203
IN - India 197
RU - Federazione Russa 164
BE - Belgio 44
HK - Hong Kong 30
VN - Vietnam 24
CZ - Repubblica Ceca 20
PL - Polonia 15
AT - Austria 12
EU - Europa 11
CA - Canada 10
IL - Israele 9
IQ - Iraq 8
IR - Iran 8
NL - Olanda 8
UZ - Uzbekistan 7
EC - Ecuador 6
AR - Argentina 5
JP - Giappone 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
GR - Grecia 4
LT - Lituania 4
MX - Messico 4
ZA - Sudafrica 4
AU - Australia 3
AZ - Azerbaigian 3
ES - Italia 3
ID - Indonesia 3
MA - Marocco 3
RO - Romania 3
TN - Tunisia 3
TW - Taiwan 3
AL - Albania 2
BD - Bangladesh 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
KG - Kirghizistan 2
KR - Corea 2
PT - Portogallo 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BY - Bielorussia 1
CO - Colombia 1
DZ - Algeria 1
EG - Egitto 1
JO - Giordania 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PY - Paraguay 1
SN - Senegal 1
TH - Thailandia 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 13.731
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.062
Chandler 1.053
Dublin 842
Singapore 803
Southend 558
Princeton 385
Izmir 329
Nanjing 306
Santa Clara 189
The Dalles 183
Cambridge 177
Wilmington 177
Beijing 166
Boardman 134
Ann Arbor 127
Nanchang 111
Dearborn 105
Ashburn 97
Altamura 91
Woodbridge 62
Chieti 61
Hebei 53
Shenyang 50
Tianjin 46
Los Angeles 44
Brussels 43
Kunming 42
Pescara 41
New York 39
Jiaxing 29
Munich 29
Hong Kong 28
Norwalk 26
Dong Ket 24
Hangzhou 23
Changsha 22
Falls Church 19
Helsinki 19
Houston 19
Kocaeli 19
Grevenbroich 18
Brno 17
Montesilvano 17
São Paulo 17
Collecorvino 16
Nuremberg 16
Washington 16
San Mateo 15
Jinan 14
Kraków 14
Lanzhou 14
Orange 14
Rome 14
Leawood 13
Moscow 13
Auburn Hills 11
Augusta 10
Guangzhou 10
Lappeenranta 10
Changchun 9
Düsseldorf 9
Milan 9
Mumbai 9
Ardabil 8
Campinas 8
Ningbo 8
Taizhou 8
Belo Horizonte 7
Pune 7
Seattle 7
Tappahannock 7
Tashkent 7
Chicago 6
Corridonia 6
Guarulhos 6
London 6
Mcallen 6
Rio de Janeiro 6
Andover 5
Finale Ligure 5
Franca 5
Frankfurt am Main 5
Goiânia 5
Hefei 5
Monmouth Junction 5
Salvador 5
Simi Valley 5
Zhengzhou 5
Anzio 4
Baghdad 4
Castignano 4
Giulianova 4
Shanghai 4
Spoltore 4
Turku 4
Vienna 4
Ancona 3
Baku 3
Bangalore 3
Caracas 3
Totale 8.135
Salva come PNG Salva come JPEG
Nome #
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 139
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 130
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 126
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 125
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 117
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 115
New Targets for Therapy in Pancreatic Cancer 114
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 113
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer 110
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 108
An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. 107
90K (Mac-2 BP) in human milk 104
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 104
ERBB3 BINDING ANTIBODY 104
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 102
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 102
Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants 102
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 102
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 101
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 100
Analisi dello stato mutazionale di K-RAS: un nuovo strumento per la selezione dei pazienti candidati a terapia con anticorpi anti-EGFR 100
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 100
Prognostic relevance of LGALS3BP in human colorectal carcinoma 99
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 97
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 97
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 96
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 96
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 96
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 95
Surgical treatment of adrenal metastases from non small cell lung cancer 94
DNA ploidy and S-phase fraction in pulmonary carcinoids. 94
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 94
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 94
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 94
Tyrosine kinase inhibitors 93
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 92
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 91
Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. 91
Novel inhibitors of pvhl-elongin c binding 91
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 90
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 90
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 89
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 88
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 88
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 87
Role of 90K protein in asthma and TH2-type cytokine expression. 87
Unknown primary tumors 86
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 86
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 85
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 85
Axillary Lymph Node Nanometastases are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients 84
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 84
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 83
Tumor-derived microvesicles: The metastasomes. 83
Prognostic value of 90K protein in HIV infection 82
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 82
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 82
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 82
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 81
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 80
Increased levels of soluble P-selectin in hypercholesterolemic patients 80
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 80
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer 80
Inhibition of the Phosphatidylinositol 3-kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects. 80
Elevated Plasma Levels of 90K (Mac-2 BP) Immunostimulatory Glycoprotein in HIV-1-Infected Children 79
Prognostic value of a novel circulating serum 90K antigen in breast cancer 79
A Stochastic Model for the HIV/AIDS Dynamic Evolution 79
Immunological effects of alternative weekly interferon–alpha–2b and low dose interleukin–2 in patients with cancer 79
DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. 79
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 79
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 77
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 77
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. 77
Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small-cell lung cancer: a pilot study. 77
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 76
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 76
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 76
Neoadjuvant Chemotherapy for Surgically Staged IIIA N2 Non-Small Cell Lung Cancer (NSCLC) in the Elderly 75
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 75
Combinations of biological response modifiers: rationale and clinical responses. 75
Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression. 75
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 75
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 74
Differential effect on TCR: CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family 73
Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer. 73
[Hairy cell leukemia: prognosis and treatment] 72
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 72
Novel P53 mutations detected by FAMA in colorectal cancers. 72
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. 72
Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells. 72
Phospholipase Cgamma1 is required for metastasis development and progression 71
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 71
Tumor-associated antigen 90K activates myelomonocytic cell line THP-1 70
Temporal trend in the level of 90K glycoprotein after HIV seroconversion among persons coinfected with hepatitis C virus 70
null 70
The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. 70
Combined therapy in pancreatic cancer 69
Tumor-associated antigen 90K activates myelomonocytic cell line THP-1. 68
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 68
Immunohistochemical and serological 90K/Mac-2BP detection in hepatocellular carcinoma patients: different behaviour of two monoclonal antibodies 67
Totale 8.792
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.758
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.758
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020247 0 0 0 0 0 0 0 0 0 0 236 11
2020/20211.180 185 9 196 10 104 229 36 15 59 194 82 61
2021/2022739 11 12 5 137 90 16 15 52 65 14 93 229
2022/20232.806 210 288 173 356 315 597 159 220 329 25 73 61
2023/20241.213 109 37 99 58 67 356 261 39 14 23 16 134
2024/20252.745 200 751 610 90 64 97 124 189 320 186 114 0
Totale 14.126